[
    [
        {
            "time": "2018-08-24",
            "original_text": "A股共发生43宗大宗交易成交7.78亿元（8月24日）",
            "features": {
                "keywords": [
                    "A股",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股共发生43宗大宗交易成交7.78亿元（8月24日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-24",
            "original_text": "贝达药业今日大宗交易成交20万股，成交价42.45元折价0.0%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大宗交易",
                    "成交价",
                    "折价率"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业今日大宗交易成交20万股，成交价42.45元折价0.0%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-24",
            "original_text": "[增持评级] 贝达药业(300558)半年报点评：降价冲击逐渐减弱 期待新产品贡献新增业绩增量",
            "features": {
                "keywords": [
                    "贝达药业",
                    "半年报",
                    "降价冲击",
                    "新产品",
                    "业绩增量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 贝达药业(300558)半年报点评：降价冲击逐渐减弱 期待新产品贡献新增业绩增量",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-24",
            "original_text": "[买入评级] 贝达药业(300558)中报点评：业绩符合预期 高研发投入持续推进 静待利润新品种上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "中报",
                    "业绩",
                    "高研发投入",
                    "新品种上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级] 贝达药业(300558)中报点评：业绩符合预期 高研发投入持续推进 静待利润新品种上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-24",
            "original_text": "[推荐评级] 贝达药业(300558)半年报点评：凯美纳继续放量 降价影响逐渐减弱 研发投入持续增加",
            "features": {
                "keywords": [
                    "贝达药业",
                    "半年报",
                    "凯美纳",
                    "降价影响",
                    "研发投入"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级] 贝达药业(300558)半年报点评：凯美纳继续放量 降价影响逐渐减弱 研发投入持续增加",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-24",
            "original_text": "[中性评级] 贝达药业(300558)中报点评：2018年1H业绩低于预期 期待下半年ALK靶向新药进展",
            "features": {
                "keywords": [
                    "贝达药业",
                    "中报",
                    "业绩",
                    "ALK靶向新药"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[中性评级] 贝达药业(300558)中报点评：2018年1H业绩低于预期 期待下半年ALK靶向新药进展",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]